HeartBeam Partners with HeartNexus to Provide 24/7 Remote Cardiology Services and Real-Time ECG Interpretation

The partnership enables HeartBeam to offer round-the-clock cardiology reader services for patients using its 3D ECG technology, expanding access to real-time cardiac monitoring outside traditional settings.

Chicago Metrowire Staff
Business
HeartBeam Partners with HeartNexus to Provide 24/7 Remote Cardiology Services and Real-Time ECG Interpretation

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, today announced a partnership with HeartNexus Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer consultations, and telemedicine visits. The collaboration enables HeartBeam to offer 24/7 cardiology reader services for patients experiencing cardiac symptoms outside traditional care settings.

Using HeartBeam's patented 3D technology, patients can capture a 30-second, cable-free ECG recording anytime symptoms occur, transmitting the data to HeartNexus cardiologists for immediate interpretation. This real-time feedback loop aims to provide faster diagnosis and intervention, potentially reducing the risk of adverse cardiac events. "Working with HeartNexus accelerates our mission to make medical-grade cardiac monitoring accessible beyond the walls of a medical facility," said Robert Eno, CEO of HeartBeam. The partnership expands HeartBeam's ecosystem with real-time cardiology feedback and future integration of AI wellness and wearable features.

The significance of this announcement lies in the growing need for remote cardiac monitoring solutions. With cardiovascular disease remaining a leading cause of death globally, timely ECG interpretation can be critical. By combining HeartBeam's portable 3D ECG device with HeartNexus's expert analysis, patients can receive professional assessments without visiting a hospital or clinic. This aligns with broader healthcare trends toward telemedicine and home-based diagnostics.

HeartBeam's platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-Lead ECG synthesis software is under FDA review. The partnership with HeartNexus not only enhances the current offering but also positions HeartBeam for future integration of AI-driven insights and wearable features, as noted by the CEO.

For more information, visit the full press release at https://ibn.fm/HqwuQ. Additional updates on HeartBeam are available at their newsroom: https://ibn.fm/BEAT.

Blockchain Registration

QR Code for Blockchain Registration